Literature DB >> 20660364

The burden of inherited leukodystrophies in children.

J L Bonkowsky1, C Nelson, J L Kingston, F M Filloux, M B Mundorff, R Srivastava.   

Abstract

OBJECTIVES: Leukodystrophies are diseases of the white matter for which data concerning clinical characteristics, incidence, disease burden, and description of outcomes are sparse. The purpose of our study was to determine the incidence and most common types of inherited leukodystrophies in a population, the mortality and time course of deaths, common neurologic features in patients, and health care costs associated with leukodystrophies.
METHODS: We conducted a retrospective, hospital- and clinic-based surveillance of inherited leukodystrophies among children younger than 18 years presenting to a regional children's hospital. We enrolled children evaluated from January 1, 1999, through December 31, 2007; clinical information was obtained from medical records. We calculated incidence based on state birth rates.
RESULTS: A total of 122 children with an inherited leukodystrophy were identified; 542 patients were excluded. A total of 49% had epilepsy, 43% required a gastrostomy tube, and 32% had a history of developmental regression. Mortality was 34%; average age at death was 8.2 years. No final diagnosis was reported in 51% of patients. The most common diagnoses were metachromatic leukodystrophy (8.2%), Pelizaeus-Merzbacher disease (7.4%), mitochondrial diseases (4.9%), and adrenoleukodystrophy (4.1%). Endocrine abnormalities and hypoplastic cerebellum were noted in significant portions of patients (15% and 14%). Average yearly per-patient medical costs were $22,579. Population incidence was 1 in 7,663 live births.
CONCLUSIONS: Inherited leukodystrophies are associated with substantial morbidity and mortality in children. Overall population incidence is higher than generally appreciated (1 in 7,663 live births). Most leukodystrophies remain undiagnosed, but a logical algorithm based on prevalence could aid testing.

Entities:  

Mesh:

Year:  2010        PMID: 20660364      PMCID: PMC2931652          DOI: 10.1212/WNL.0b013e3181eee46b

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  27 in total

1.  Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening.

Authors:  L Bezman; A B Moser; G V Raymond; P Rinaldo; P A Watkins; K D Smith; N E Kass; H W Moser
Journal:  Ann Neurol       Date:  2001-04       Impact factor: 10.422

2.  Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity.

Authors:  Stephan Harbarth; John P Burke; James F Lloyd; R Scott Evans; Stanley L Pestotnik; Matthew H Samore
Journal:  Clin Infect Dis       Date:  2002-12-02       Impact factor: 9.079

3.  Defining and categorizing leukoencephalopathies of unknown origin: MR imaging approach.

Authors:  M S van der Knaap; S N Breiter; S Naidu; A A Hart; J Valk
Journal:  Radiology       Date:  1999-10       Impact factor: 11.105

Review 4.  Leukodystrophies: recent developments in genetics, molecular biology, pathogenesis and treatment.

Authors:  J Berger; H W Moser; S Forss-Petter
Journal:  Curr Opin Neurol       Date:  2001-06       Impact factor: 5.710

Review 5.  Update on genetic disorders affecting white matter.

Authors:  E M Kaye
Journal:  Pediatr Neurol       Date:  2001-01       Impact factor: 3.372

6.  The life expectancy of profoundly handicapped people with mental retardation.

Authors:  R K Eyman; H J Grossman; R H Chaney; T L Call
Journal:  N Engl J Med       Date:  1990-08-30       Impact factor: 91.245

7.  Leukoencephalopathy, cerebral calcifications, and cysts: new observations.

Authors:  L M Nagae-Poetscher; G Bibat; M Philippart; S Rosemberg; A Fatemi; M T C Lacerda; M O R Costa; F Kok; C Costa Leite; A Horská; P B Barker; S Naidu
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

Review 8.  Delayed tooth eruption: pathogenesis, diagnosis, and treatment. A literature review.

Authors:  Lokesh Suri; Eleni Gagari; Heleni Vastardis
Journal:  Am J Orthod Dentofacial Orthop       Date:  2004-10       Impact factor: 2.650

9.  The epidemiology of progressive encephalopathies in childhood. I. Live birth prevalence in west Sweden.

Authors:  P Uvebrant; K Lanneskog; B Hagberg
Journal:  Neuropediatrics       Date:  1992-08       Impact factor: 1.947

View more
  66 in total

1.  National variation in costs and mortality for leukodystrophy patients in US children's hospitals.

Authors:  Cameron J Brimley; Jonathan Lopez; Keith van Haren; Jacob Wilkes; Xiaoming Sheng; Clint Nelson; E Kent Korgenski; Rajendu Srivastava; Joshua L Bonkowsky
Journal:  Pediatr Neurol       Date:  2013-09       Impact factor: 3.372

2.  Absence of Axoglial Paranodal Junctions in a Child With CNTNAP1 Mutations, Hypomyelination, and Arthrogryposis.

Authors:  Alexander Conant; Julian Curiel; Amy Pizzino; Parisa Sabetrasekh; Jennifer Murphy; Miriam Bloom; Sarah H Evans; Guy Helman; Ryan J Taft; Cas Simons; Matthew T Whitehead; Steven A Moore; Adeline Vanderver
Journal:  J Child Neurol       Date:  2018-06-08       Impact factor: 1.987

Review 3.  Case definition and classification of leukodystrophies and leukoencephalopathies.

Authors:  Adeline Vanderver; Morgan Prust; Davide Tonduti; Fanny Mochel; Heather M Hussey; Guy Helman; James Garbern; Florian Eichler; Pierre Labauge; Patrick Aubourg; Diana Rodriguez; Marc C Patterson; Johan L K Van Hove; Johanna Schmidt; Nicole I Wolf; Odile Boespflug-Tanguy; Raphael Schiffmann; Marjo S van der Knaap
Journal:  Mol Genet Metab       Date:  2015-01-29       Impact factor: 4.797

4.  Targeted leukodystrophy diagnosis based on charges and yields for testing.

Authors:  Jackson Richards; E Kent Korgenski; Ryan J Taft; Adeline Vanderver; Joshua L Bonkowsky
Journal:  Am J Med Genet A       Date:  2015-07-16       Impact factor: 2.802

5.  Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies.

Authors:  Laura A Adang; Omar Sherbini; Laura Ball; Miriam Bloom; Anil Darbari; Hernan Amartino; Donna DiVito; Florian Eichler; Maria Escolar; Sarah H Evans; Ali Fatemi; Jamie Fraser; Leslie Hollowell; Nicole Jaffe; Christopher Joseph; Mary Karpinski; Stephanie Keller; Ryan Maddock; Edna Mancilla; Bruce McClary; Jana Mertz; Kiley Morgart; Thomas Langan; Richard Leventer; Sumit Parikh; Amy Pizzino; Erin Prange; Deborah L Renaud; William Rizzo; Jay Shapiro; Dean Suhr; Teryn Suhr; Davide Tonduti; Jacque Waggoner; Amy Waldman; Nicole I Wolf; Ayelet Zerem; Joshua L Bonkowsky; Genevieve Bernard; Keith van Haren; Adeline Vanderver
Journal:  Mol Genet Metab       Date:  2017-08-20       Impact factor: 4.797

6.  Elevated Leukodystrophy Incidence Predicted From Genomics Databases.

Authors:  Haille E Soderholm; Alexander B Chapin; Pinar Bayrak-Toydemir; Joshua L Bonkowsky
Journal:  Pediatr Neurol       Date:  2020-06-17       Impact factor: 3.372

7.  Racial/Ethnic and Insurance Status Disparities in Distance Traveled to Access Children's Hospital Care for Severe Illness: the Case of Children with Leukodystrophies.

Authors:  Sara E Grineski; Danielle X Morales; Timothy Collins; Jacob Wilkes; Joshua L Bonkowsky
Journal:  J Racial Ethn Health Disparities       Date:  2020-02-24

8.  Relative incidence of inherited white matter disorders in childhood to acquired pediatric demyelinating disorders.

Authors:  Adeline Vanderver; Heather Hussey; Johanna L Schmidt; William Pastor; Heather J Hoffman
Journal:  Semin Pediatr Neurol       Date:  2012-12       Impact factor: 1.636

9.  Determinants of health care use in a population-based leukodystrophy cohort.

Authors:  Clint Nelson; Michael B Mundorff; E Kent Korgenski; Cameron J Brimley; Rajendu Srivastava; Joshua L Bonkowsky
Journal:  J Pediatr       Date:  2012-10-13       Impact factor: 4.406

10.  Lamin B1 mediates cell-autonomous neuropathology in a leukodystrophy mouse model.

Authors:  Mary Y Heng; Shu-Ting Lin; Laure Verret; Yong Huang; Sherry Kamiya; Quasar S Padiath; Ying Tong; Jorge J Palop; Eric J Huang; Louis J Ptáček; Ying-Hui Fu
Journal:  J Clin Invest       Date:  2013-05-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.